



Brussels, 21.12.2020  
C(2020) 9598 final

**COMMISSION IMPLEMENTING DECISION**

**of 21.12.2020**

**granting a conditional marketing authorisation under Regulation (EC) No 726/2004 of the European Parliament and of the Council for "Comirnaty - COVID-19 mRNA Vaccine (nucleoside modified)", a medicinal product for human use**

(Text with EEA relevance)

(ONLY THE ENGLISH TEXT IS AUTHENTIC)

## COMMISSION IMPLEMENTING DECISION

of 21.12.2020

**granting a conditional marketing authorisation under Regulation (EC) No 726/2004 of the European Parliament and of the Council for "Comirnaty - COVID-19 mRNA Vaccine (nucleoside modified)", a medicinal product for human use**

(Text with EEA relevance)

(ONLY THE ENGLISH TEXT IS AUTHENTIC)

THE EUROPEAN COMMISSION,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency<sup>1</sup>, and in particular Article 10(2) and 14-a thereof,

Having regard to Commission Regulation (EC) No 507/2006 on the conditional marketing authorisation for medicinal products for human use falling within the scope of Regulation (EC) No 726/2004 of the European Parliament and of the Council<sup>2</sup>,

Having regard to the application submitted by BioNTech Manufacturing GmbH, on 1 December 2020, under Article 4(1) of Regulation (EC) No 726/2004,

Having regard to the opinion of the European Medicines Agency, formulated on 21 December 2020 by the Committee for Medicinal Products for Human Use,

Whereas:

- (1) The medicinal product "Comirnaty - COVID-19 mRNA Vaccine (nucleoside modified)" complies with the requirements set out in Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use<sup>3</sup>.
- (2) "Comirnaty - COVID-19 mRNA Vaccine (nucleoside modified)" falls within the scope of Regulation (EC) No 507/2006, in particular Article 2(1). In addition, as set out in Annex IV, the medicinal product meets the requirements of Article 4 of this Regulation for the granting of a conditional marketing authorisation.
- (3) Authorisation for the placing on the market of "Comirnaty - COVID-19 mRNA Vaccine (nucleoside modified)" should therefore be granted subject to certain requirements, in accordance with Article 14-a of Regulation (EC) No 726/2004 and Regulation (EC) No 507/2006.

---

<sup>1</sup> OJ L 136, 30.4.2004, p. 1.

<sup>2</sup> OJ L 92, 30.3.2006, p. 6.

<sup>3</sup> OJ L 311, 28.11.2001, p. 67.

- (4) The Committee for Medicinal Products for Human Use considered that "Single-stranded, 5'-capped messenger RNA produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2" is a new active substance.
- (5) The measures provided for in this Decision are in accordance with the opinion of the Standing Committee on Medicinal Products for Human Use,

HAS ADOPTED THIS DECISION:

#### *Article 1*

The conditional marketing authorisation provided for in Article 3 and 14-a of Regulation (EC) No 726/2004 is granted for the medicinal product "Comirnaty - COVID-19 mRNA Vaccine (nucleoside modified)", the characteristics of which are summarised in Annex I to this Decision. "Comirnaty - COVID-19 mRNA Vaccine (nucleoside modified)" shall be registered in the Union Register of Medicinal Products under number EU/1/20/1528.

#### *Article 2*

The marketing authorisation concerning the medicinal product referred to in Article 1 shall be subject to compliance with the requirements and specifications set out in Annex II, including with regard to manufacturing. Those requirements shall be reviewed annually.

#### *Article 3*

The labelling and package leaflet concerning the medicinal product referred to in Article 1 shall comply with the conditions set out in Annex III.

#### *Article 4*

The period of validity of the authorisation shall be one year from the date of notification of this Decision.

*Article 5*

This Decision is addressed to BioNTech Manufacturing GmbH, An der Goldgrube 12, 55131 Mainz, Deutschland.

Done at Brussels, 21.12.2020

*For the Commission*

*Margaritis SCHINAS*

*Vice-President*

